Acute Pain Market Poised for 12% Growth Through 2036

This growth is underpinned by the rising global volume of orthopedic and cardiovascular surgeries, which generates constant demand for effective postoperative analgesia. As healthcare providers prioritize patient safety and minimize the risk of addiction, the industry is funneling investment into a robust pipeline of novel, non-opioid candidates. Among these are promising therapies such as Gensco Pharma and IntelGenx’s RizaFilm, Cali Biosciences’ CPL-01, and Neumentum’s NTM-001, a ready-to-use ketorolac infusion designed for continuous pain management.

The competitive landscape remains dynamic, characterized by both high-stakes innovation and regulatory attrition. While the sector has seen the withdrawal of certain therapies like DSUVIA and OLINVYK due to commercial hurdles, recent advancements offer a more optimistic outlook. Notably, Vertex Pharmaceuticals has advanced its NaV1.8 inhibitor, suzetrigine, which represents a potential new class of oral analgesics. These emerging options, combined with established multimodal regimens that integrate regional anesthesia and physical rehabilitation, suggest a fundamental transformation in how acute pain is managed globally.